ANL
Price
$9.87
Change
-$0.81 (-7.58%)
Updated
Jul 10 closing price
Capitalization
635.61M
26 days until earnings call
Intraday BUY SELL Signals
REVB
Price
$0.99
Change
+$0.01 (+1.01%)
Updated
Jul 10 closing price
Capitalization
3.91M
27 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANL vs REVB

ANL vs REVB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ANL vs. REVB commentary
Jul 11, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANL is a Hold and REVB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2026
Stock price -- (ANL: $9.87 vs. REVB: $1.00)
Brand notoriety: ANL and REVB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANL: 84% vs. REVB: 29%
Market capitalization -- ANL: $635.61M vs. REVB: $3.91M
ANL [@Biotechnology] is valued at $635.61M. REVB’s [@Biotechnology] market capitalization is $3.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $123.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANL’s FA Score shows that 0 FA rating(s) are green whileREVB’s FA Score has 2 green FA rating(s).

  • ANL’s FA Score: 0 green, 5 red.
  • REVB’s FA Score: 2 green, 3 red.
According to our system of comparison, REVB is a better buy in the long-term than ANL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANL’s TA Score shows that 2 TA indicator(s) are bullish while REVB’s TA Score has 4 bullish TA indicator(s).

  • ANL’s TA Score: 2 bullish, 6 bearish.
  • REVB’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, REVB is a better buy in the short-term than ANL.

Price Growth

ANL (@Biotechnology) experienced а +4.00% price change this week, while REVB (@Biotechnology) price change was -7.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.42%. For the same industry, the average monthly price growth was +13.23%, and the average quarterly price growth was +1883.80%.

Reported Earning Dates

ANL is expected to report earnings on Aug 06, 2026.

REVB is expected to report earnings on Aug 07, 2026.

Industries' Descriptions

@Biotechnology (-0.42% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANL($636M) has a higher market cap than REVB($3.91M). ANL YTD gains are higher at: 595.070 vs. REVB (-68.898). REVB has higher annual earnings (EBITDA): -10.04M vs. ANL (-49.89M). ANL has more cash in the bank: 98M vs. REVB (14.1M). REVB has less debt than ANL: REVB (759K) vs ANL (39.5M). ANL has higher revenues than REVB: ANL (5M) vs REVB (0).
ANLREVBANL / REVB
Capitalization636M3.91M16,274%
EBITDA-49.89M-10.04M497%
Gain YTD595.070-68.898-864%
P/E RatioN/A0.00-
Revenue5M0-
Total Cash98M14.1M695%
Total Debt39.5M759K5,204%
TECHNICAL ANALYSIS
Technical Analysis
ANLREVB
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
71%
MACD
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 17 days ago
79%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 16 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ANL
Daily Signal:
Gain/Loss:
REVB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARTL1.080.06
+5.88%
Artelo Biosciences Inc
DHT17.760.83
+4.90%
DHT Holdings
ONTO321.444.42
+1.39%
Onto Innovation
CBNK35.070.15
+0.43%
Capital Bancorp
PTHS27.16N/A
N/A
Pelthos Therapeutics Inc

ANL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANL has been loosely correlated with MSLE. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ANL jumps, then MSLE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANL
1D Price
Change %
ANL100%
-7.58%
MSLE - ANL
40%
Loosely correlated
+3.71%
REVB - ANL
33%
Loosely correlated
+0.51%
SER - ANL
23%
Poorly correlated
N/A
HYPD - ANL
23%
Poorly correlated
-0.96%
MOLN - ANL
23%
Poorly correlated
+0.75%
More

REVB and

Correlation & Price change

A.I.dvisor indicates that over the last year, REVB has been closely correlated with INKT. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if REVB jumps, then INKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REVB
1D Price
Change %
REVB100%
+0.51%
INKT - REVB
80%
Closely correlated
-3.58%
GNPX - REVB
48%
Loosely correlated
+0.79%
SABS - REVB
48%
Loosely correlated
-3.54%
TCRT - REVB
46%
Loosely correlated
-2.42%
OGEN - REVB
34%
Loosely correlated
N/A
More